Navigation Links
ThromboGenics N.V.: Business Update
Date:11/6/2008

howed that microplasmin-treated patients had a statistically significant improvement in the level of damage to the blood brain barrier compared to placebo-treated patients, measured using the marker of matrix metalloproteinase (MMP). MMP activation plays a crucial role in the pathogenesis of brain edema and hemorrhagic transformation after ischemic stroke.

It remains ThromboGenics' intention that it will only move forward with the development of microplasmin for the treatment of stroke in cooperation with a partner. This view is based on both the risks and cost associated with the development of new stroke therapies, and the Company's desire to invest in its other attractive pipeline product candidates, including microplasmin in the treatment of back of the eye diseases.

Staphylokinase (THR-100)

ThromboGenics partner for the clinical development and commercialization of THR-100, Bharat Biotech, continues to work with the Indian authorities to gain the necessary approvals to begin a Phase III trial with this novel variant of Recombinant Staphylokinase. The initial trial will evaluate THR-100 for the treatment of acute myocardial infarction (AMI), or heart attack. Given the commercial strengths of Bharat in this market and the clinical advantages of THR-100, it is hoped that this novel product will quickly become the market leader for the thrombolytic treatment of heart attacks in India.

TB-403 - Working with Roche on this Potential Breakthrough Cancer Treatment

ThromboGenics, in conjunction with its partner BioInvent, has made good progress in transferring this novel anti-cancer agent to Roche following the strategic alliance signed in June 2008.

Following the successful completion of the initial Phase I study, the parties have begun a Phase Ib trial with TB-403 in end-stage cancer patients. This study, which will recruit approximately 24 patients, is designed to provide both safety data on TB-403 when used in cancer patients
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... (PRWEB) July 30, 2014 Selexis ... for biologic drug discovery and mammalian cell line development, ... CHO-Mplus Libraries ™ will be presented at the 10th ... being held, September 8 – 10, 2014 at the ... , The following abstract will be presented during ...
(Date:7/30/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its ... Applications , the global market for industrial enzymes is ... registering a five-year compound annual growth rate (CAGR) of ... the detergent enzyme segment with a CAGR of 11.3% ... almost every sector of industrial activity, ranging from technical ...
(Date:7/30/2014)... 30, 2014 Researchers often use microelectronic ... but such devices can do much more – ... such, researchers have looked to patterned assemblies of ... metabolic engineering to characterize – and potentially control ... are envisioned to recreate animal and human physiological ...
(Date:7/30/2014)... 2014 Connecticut Center for Advanced Technology, ... East Hartford, Conn., was awarded a Rural Business Enterprise ... project that will determine the feasibility of implementing an ... USDA Rural Development provided $53,000 for CCAT under the ... phase of the feasibility study in fiscal year 2014. ...
Breaking Biology Technology:Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3
... SAN FRANCISCO, Nov. 12 VIA Pharmaceuticals,(Nasdaq: ... on the development of,compounds for the treatment ... its clinical advisory board. Joining the clinical ... Professor of Medicine,Harvard Medical School, and Senior ...
... Associated with Chronic Pain Conditions in Patients Who ... ... FRAZER, Pa., Nov. 12 Cephalon, Inc. (Nasdaq:,CEPH) today announced ... Food and Drug Administration (FDA) seeking approval to,market FENTORA(R) (fentanyl buccal ...
... N.J. -- The Edwin A. Stevens Society of Stevens Institute ... School of Systems and Enterprises, Dr. Dinesh Verma, with the ... at the Park Avenue Club in Florham Park, N.J., Nov. ... is by invitation only., The Presidents Leadership Award is presented ...
Cached Biology Technology:VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease 2VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease 3VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease 4Cephalon Submits Supplemental New Drug Application for FENTORA 2Cephalon Submits Supplemental New Drug Application for FENTORA 3Cephalon Submits Supplemental New Drug Application for FENTORA 4Cephalon Submits Supplemental New Drug Application for FENTORA 5Cephalon Submits Supplemental New Drug Application for FENTORA 6Cephalon Submits Supplemental New Drug Application for FENTORA 7Dr. Dinesh Verma to be honored with President's Leadership Award at Edwin A. Stevens Society Gala 2Dr. Dinesh Verma to be honored with President's Leadership Award at Edwin A. Stevens Society Gala 3
(Date:7/30/2014)... iodine-125 (125I) in cancer treatment has been shown ... are critical for neural transmission between the peripheral ... colleagues from Institute of Radiation Medicine, Chinese Academy ... be implanted into rat dorsal root ganglia (DRG) ... with different radioactivity (0, 14.8, 29.6 MBq) were ...
(Date:7/30/2014)... first high-resolution map of the carbon stocks stored ... The new and improved methodology used to make ... market-based carbon economies. The new carbon map ... it provides the critical input to studies of ... and enforcement purposes. The technique includes the determination ...
(Date:7/29/2014)... researchers sometimes need to get back to basics. ... to study the impacts of the bumphead parrotfish ... at two remote locations in the central Pacific ... computer simulation, McCauley, an assistant professor in the ... his colleagues sought to understand whether the world,s ...
Breaking Biology News(10 mins):Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3Underwater elephants 2Underwater elephants 3
... University of Illinois scientists have learned that a specific ... health. "In experiments with mice, we knocked out ... body to make arachidonic acid. Without arachidonic acid, the ... itchy, they scratched themselves continuously, and they developed a ...
... A team of researchers from the United States and Europe ... a role in the etiology of common forms of kidney ... variations in DNA sequences in more than 65,000 individuals of ... be more frequent among people with poor kidney function or ...
... Just one "pulse" of artificial light at night disrupts ... by Dr. Rachel Ben-Shlomo of the University of Haifa-Oranim ... Charalambos P. Kyriacou of the University of Leicester. "Damage ... is therefore important to understand the causes of this ...
Cached Biology News:U of I study: Lack of omega-6 fatty acid linked to severe dermatitis 2International research team discovers novel genes influencing kidney disease risk 2
... thermal cycler is a compact instrument for gene ... tubes, 12 x 0.5 ml tubes, or a ... a thumbwheel to adjust height and pressure to ... heat pumps provide excellent thermal performance, and the ...
MiniCycler thermal cycler with Hot Bonnet heated lid, holds 25x0.2ml tubes...
... with SR-101 Labeled Substrates (red fluorescence; ... measure serine protease activation • No ... FLISP Kits utilize cell-permeable, fluorescently labeled ... measure chymotrypsin-like activity in whole living ...
... MitoPT kit is used in conjunction with your ... and induce apoptosis according to your existing procedure ... a negative control). Once you have induced apoptosis ... to each population and incubate the cells for ...
Biology Products: